Session 1 5 agenda for of mm2 marketing strategy
Download
1 / 12

- PowerPoint PPT Presentation


  • 184 Views
  • Uploaded on

Session #1 5 : Agenda for of MM2– MARKETING STRATEGY. Brief Review The Zantac Case: Market Leadership. Review of Class Session 13: Major Points of the ODI Case. Successfully introducing really new products is very difficult and most likely to fail (for variety of reasons)

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about '' - jeneva


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Session 1 5 agenda for of mm2 marketing strategy l.jpg
Session #15:Agenda for of MM2– MARKETING STRATEGY

  • Brief Review

  • The Zantac Case: Market Leadership


Review of class session 13 major points of the odi case l.jpg
Review ofClass Session 13: Major Points of the ODI Case

  • Successfully introducing really new products is very difficult and most likely to fail (for variety of reasons)

    • ‘Simple implementation problems’ can kill an otherwise good product

  • Important to anticipate & confront consumer objections to product adoption

    • Various types of risks


Attributes of innovations that improve detract from their chances of adoption by consumers l.jpg
Attributes of Innovations that Improve/Detract from their Chances of Adoption by Consumers

  • The Relative advantage of the innovation over the products/procedures it is designed to supersede.

  • Its perceived complexity.

  • Its compatibility in use with present behavior patterns and complementary products.

  • The ease with which its features (especially its benefits) can be observed and communicated.

  • The degree of risk (physical, financial & social) attached to adoption of the innovation in preference to existing products or procedures.

  • The extent to which the innovation can be tried on a limited basis before being adopted on a large scale, permanent basis.


Extent of zantac s success time of case l.jpg
Extent of Zantac’s Success (time of case) Chances of Adoption by Consumers

  • Zantac is #1 pharmaceutical product worldwide

    • 1.8% share  whole of #10 firm (Sandoz; 2.1% share)

  • Glaxo rose from minor pharmaceutical firm to #3 worldwide on strength of Zantac

  • In 1981 Glaxo’s US sales were small; By 1989

    • held 53% of US market

    • US accounted for 41% of Glaxo’s sales

  • Between 81-89 Glaxo was the most profitable large company in the world in any sector

    • ROI increased from 16.5% (1981) to 30% (1989).


Tagament vs zantac l.jpg
Tagament vs. Zantac Chances of Adoption by Consumers

Customer Needs (by order of

Ideal Performance

Tagamet

Zantac

importance)

no difference indicated in

Pain Relief

|-----------2------------|

Immediately

after several days (p. 5)

case

Healing Speed*

|--------T---Z----------|

Immediately

after 6 weeks

after 4 weeks

Healing Efficacy

|----------------2-------|

100%

80% of patients

80% of patients

breast swelling in males

Side Effects**

|----------------------2-|

None

reversible liver damage

none known

mental confusion

Anti-Coagulants

Interactions**

|----------------------2-|

None

none known

Valium

Once a day or

4/day

Convenience

|------T-----Z----------|

2/day

less

2/day approved

Recurrence (after

same as Tagamet (see

|-----2------------------|

None

66% within a year

healing)

Ex. 10)

Recurrence (during

continuous

|-------------------------|

None

unknown in 1981

unknown in 1981

treatment)

*actual healing is difficult to judge for patients and doctors without a test after treatment (p. 3)

**Perception: Tagamet is very safe


Zantac sales potential l.jpg

Zantac is a me-too product Chances of Adoption by Consumers

Pioneers enjoy a lasting advantage

Tagamet’s side effects not an issue

Tagamet’s safety record will be more important than Zantac’s zero side effects

Tagamet’s economies of scale make low-price policy unattractive

Weak Glaxo presence in US

True

Only if they stay awake

True, but are they known

Who says?

Net profit margin of 28% on Tagamet leaves room

True

Zantac Sales Potential

Conventional logicObservation


Obstacles vs glaxo actions l.jpg
Obstacles vs. Glaxo Actions Chances of Adoption by Consumers


Zantac what next l.jpg
Zantac: What Next? Chances of Adoption by Consumers


Zantac key points l.jpg
Zantac: Key Points Chances of Adoption by Consumers

  • A minor product advantage can be leveraged into a competitive advantage by creating the right customer perceptions.

    • Good & consistent positioning

      • Zantac: fast, simple, specific

    • Align all Ps to create this positioning

      • Price: understand customers’ interpretation (quality) understand economic incentives

      • Sales effort/communication: high share-of-voice

      • Focused & clear advertising messages

    • Having ineffective competitors helps..


Attacking market leader l.jpg
Attacking Market Leader Chances of Adoption by Consumers

  • To overcome disadvantage (poor fit): size & resources

    • Strategic partnerships (Glaxo-Menarini, Glaxo-Roche, …)

    • Focus (Glaxo concentrated on Zantac, while SK diluted its resources)

  • Overcome disadvantage: Dominant incumbent

    • Attack under-defended markets (European markets first before attacking SK in U.S. market)

    • Attack competitor’s “blind spots” (safety and convenience)

  • Anticipate competitive reactions

    • Understand history and competitor’s past behavior (Glaxo understands SK’s mistakes; Glaxo is a very aggressive competitor)

    • Analyze competitor’s motivation to react (Zantac is Glaxo’s life)

    • Prepare contingency plans (Need to think several steps ahead)


Defending leadership l.jpg
Defending Leadership Chances of Adoption by Consumers

  • Despite patent protection, product advantages are not sustainable for long; for optimal leverage of such advantages, continuous innovation & speed are essential. Markets are speeding up:

    • During product development: time-to-market

    • During roll-out: time to global coverage

    • During market penetration: time to market share peak

  • To sustain a differentiated position, market leaders ought to

    • Understand the gaps between customer needs and existing product offerings, and close them faster than competitors

    • Develop new market segments

    • Maintain high levels of marketing investments

    • Understand competitors’ weaknesses and utilize them appropriately


Threats to sustainability s i s l.jpg
Threats to Sustainability (S.I.S.) Chances of Adoption by Consumers

  • Slack

    • complacency, inefficiency

  • Imitation

    • copy-cats

      • Zantac to Tagamet

  • Substitutes

    • satisfy same customer needs in a different way

      • Tagamet to stomach surgery